Should I Buy ZTS? ZTS 2026 Analysis

Should You Buy Zoetis Inc (ZTS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

127.420

1 Day change

0.54%

52 Week Range

177.000

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ZTS is not a good buy right now for an impatient investor. The stock’s broader trend remains bearish (SMA_200 > SMA_20 > SMA_5) and there’s no proprietary “must-buy” trigger today (no AI Stock Picker or SwingMax signal). While options positioning looks bullish and hedge funds have been buying, the lack of near-term catalysts (no recent news; next major event is earnings on 2026-02-12 pre-market) plus a clear recent wave of analyst downgrades/price-target cuts makes the risk/reward unattractive for an immediate entry.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Trend/structure: Bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) signals the prevailing downtrend is still intact. Momentum: MACD histogram is negative (-0.248) but negatively contracting, suggesting downside momentum is fading (early stabilization), not a confirmed reversal. RSI: RSI_6 at ~55.7 is neutral—no oversold bounce setup and no breakout momentum. Levels: Pivot ~123.69 is the near-term decision point. Support: ~120.99 then ~119.32. Resistance: ~126.38 then ~128.05. With price at ~124.11, upside is capped by nearby resistance while trend remains bearish, favoring “hold” rather than chasing a fresh buy.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Put/call ratios are low (OI PCR 0.47; volume PCR 0.31), indicating call-heavy positioning (bullish/less hedging). Activity: Today’s options volume is elevated vs the 30-day average (~~148%), and open interest is also elevated vs average (~~130%), suggesting increased attention. Volatility: 30D IV ~~27.66 with IV percentile ~51 (mid-range), not signaling extreme fear; IV rank is low (~~5.65), implying IV is relatively low compared with its own recent range—more consistent with calm/bullish positioning than panic hedging. Bottom line: Options flow leans bullish, but it hasn’t yet translated into a confirmed bullish price trend on the chart.

Technical Summary

Sell

Buy

Positive Catalysts

scheduled for 2026-02-12 pre-market.

Neutral/Negative Catalysts

Technical trend remains bearish: Moving-average structure is still negative (SMA_200 > SMA_20 > SMA_5), and MACD is below zero.
Analyst sentiment has weakened: multiple downgrades to Neutral/Hold and sharp price target cuts, reflecting concerns about near-term innovation/launch timing and demand/price-value dynamics.
No supportive news flow in the past week to spark an immediate re-rating.
Overhang from product/competition commentary: Street notes cite headwinds in OA pain mAb launches and increased competition in key franchises (per recent initiations/notes).

Financial Performance

Latest quarter: 2025/Q3. Revenue: $2.40B, +0.50% YoY (modest top-line growth). Net income: $721M, +5.72% YoY (profit growing faster than revenue). EPS: $1.63, +8.67% YoY (solid per-share growth). Gross margin: ~70.25%, +1.43% YoY (continued margin strength). Takeaway: Quality earnings/margins, but revenue growth is currently low—consistent with the Street’s “air pocket”/near-term innovation gap narrative.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings and targets have moved meaningfully more cautious.

Piper Sandler (2026-01-22): Downgraded to Neutral from Overweight; PT cut to $135 from $190, citing an “innovation air pocket” and concerns about estimates over the next 1–2 years.
UBS (2026-01-29): Kept Neutral; PT trimmed to $136 from $141.
BofA (2025-12-15): Downgraded to Neutral from Buy; PT to $135 from $165.
Stifel (2025-11-18): Hold; PT to $130 from $140.
Morgan Stanley (2025-12-18): Still Overweight; PT to $160 from $175 (more supportive outlier).
Barclays/KeyBanc initiations: Equal Weight / Sector Weight (generally “fairly valued / wait for catalysts”). Wall Street pros: strong long-term portfolio, margin strength, and eventual innovation cycle. Wall Street cons: near-term innovation/launch gap, competitive pressure in key areas, and skepticism that forward estimates (especially 2026) are achievable—limiting willingness to buy aggressively today.

Influential/political trading check: No recent congress trading data available; insider activity is described as neutral with no significant recent trend.

ZTS Should I Buy